OmniAb

OMNIAB INC

OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.

Oil,Field,Site,,In,The,Evening,,Oil,Pumps,Are,Running

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ATER

OABI

ONVO

Dow Surges Over 200 Points; US Crude Oil Inventories Increase More than Expected

Penny Stocks

Small Cap

General

ANET

LULU

MSTR

OLPX

PTON

SMMT

SNOW

Director of Lululemon Purchases Shares After Large Drop – Insider Weekends

Long Ideas

Insider Trades

Pre-Market Outlook

HNRG

PPBI

Although U.S. stocks closed lower on Monday, there were a few notable insider trades.

Over $1M Bet On OmniAb? Check Out These 3 Stocks Insiders Are Buying

OmniAb Inc

Press Releases

OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights

OmniAb to Participate in Two Investor Conferences in September

OmniAb to Report Third Quarter 2024 Financial Results on November 12

OmniAb to Participate in Two Investor Conferences in November

OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights

OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference

Kuehn Law Encourages Investors of OmniAb, Inc. to Contact Law Firm

OmniAb to Participate in Two Investor Conferences in March

OmniAb to Report Fourth Quarter 2024 Financial Results on March 18

OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Akoya Biosciences

Atlantic International Corp. - Common Stock

Atlantic International

Codexis

Champions Oncology

Cytek Biosciences

CryoPort

Fortrea Holdings

Standard BioTools

Lifecore Biomedical

Mesa Laboratories

Maravai LifeSciences Holdings, Inc. - Class A common stock

Maravai LifeSciences

MaxCyte

Niagen Bioscience

Nautilus Biotechnology, Inc. - Common Stock

Nautilus Biotechnology

Inotiv

Pacific Biosciences of California, Inc. - Common Stock

Pacific Biosciences

Personalis

Quantum-Si Incorporated - Class A Common Stock

Quantum-Si

Quanterix

Rapid Micro Biosystems, Inc. - Class A Common Stock

Rapid Micro Biosystems

Seer

Alpha Teknova

10x Genomics

RBC Capital

Benchmark

HC Wainwright & Co.

Truist Securities

Craig-Hallum

Comments

OmniAb

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga